# Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

> **NCT01884311** · PHASE3 · COMPLETED · sponsor: **Bio Products Laboratory** · enrollment: 38 (actual)

## Conditions studied

- Primary Immune Deficiency Disorders
- Common Variable Immunodeficiency
- X-linked Agammaglobulinaemia
- Hyperimmunoglobulin M Syndrome

## Interventions

- **BIOLOGICAL:** Subgam

## Key facts

- **NCT ID:** NCT01884311
- **Lead sponsor:** Bio Products Laboratory
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-20
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-05-25
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884311, "Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01884311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*